

Special Issue

Vaccination Strategies as We Face Another Year of the COVID-19 Pandemic

Message from the Guest Editor

We are now in the third year of the COVID-19 pandemic, and we are constantly seeking solutions to ensure effective prevention of this disease. Ongoing clinical trials are providing new data on the safety and efficacy of COVID-19 vaccination in different age groups, optimal vaccination schedules, and timing of subsequent booster doses. Particular attention should be paid to patients in risk groups who may have reduced vaccine response. Hence, it is necessary to consider the possibility of administering a third dose of basic vaccination to these patients and to determine the timing of booster doses. During the pandemic period, there was a delay and reduction in the number of vaccinations being carried out. Hence, there is a need to immediately compensate for delays in the implementation of immunizations according to national vaccination programs, to introduce widely available coadministration of vaccines with COVID-19 vaccination. It is also necessary to extend the use of the influenza vaccine. For this Special Issue, we discuss strategies for vaccinating against COVID-19 as well as combining this vaccination with the prevention of other infectious diseases.

Guest Editor

Prof. Dr. Hanna Czajka

1. College of Medical Sciences, University of Rzeszów, 35-315 Rzeszów, Poland
2. Infectious Diseases Outpatient Clinic, St. Louis Regional Specialised Children's Hospital, 31-503 Cracow, Poland

Deadline for manuscript submissions

closed (31 December 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/116865

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).